Daxor Corporation (NASDAQ:DXR) Stock Short Interest Falls 69.7%

Daxor Corporation (NASDAQ:DXR) saw a significant decline in short interest during the month of October. As of October 30th, there was short interest totaling 1,022 shares, a decline of 69.7% from the October 15th total of 3,374 shares. Based on an average trading volume of 11,538 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the company’s stock are sold short.

Daxor Stock Down 0.4%

Daxor stock traded down $0.03 during trading hours on Friday, reaching $8.43. 16,805 shares of the stock were exchanged, compared to its average volume of 11,660. The firm’s 50 day moving average is $10.14 and its 200 day moving average is $10.55. Daxor has a 52-week low of $8.24 and a 52-week high of $14.76.

Institutional Investors Weigh In On Daxor

A number of hedge funds and other institutional investors have recently modified their holdings of DXR. Aristides Capital LLC acquired a new stake in Daxor in the first quarter valued at $403,000. Susquehanna International Group LLP increased its holdings in shares of Daxor by 97.7% during the 2nd quarter. Susquehanna International Group LLP now owns 27,131 shares of the company’s stock worth $275,000 after buying an additional 13,411 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new position in shares of Daxor in the 1st quarter worth about $245,000. Finally, Crescent Grove Advisors LLC acquired a new position in Daxor during the first quarter valued at approximately $104,000. 1.34% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Daxor from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

About Daxor

Daxor Corporation (NASDAQ: DXR) is a medical device and biotechnology company focused on blood-volume measurement and related diagnostic applications. Its primary product is the BVA-100 Blood Volume Analyzer, a system designed to measure a patient’s total blood volume, plasma volume, red blood cell volume and hematocrit. The BVA-100 uses a blood sample and an iodine-131-labeled albumin tracer to provide quantitative blood-volume measurements. The technology is intended to support clinical assessment and management in areas including heart failure, critical care, kidney disease, blood disorders and perioperative care, where accurate information about a patient’s fluid and blood-volume status can assist treatment decisions.